BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Cellular senescence: a promising strategy for cancer therapy

  • Lee, Seongju (Hypoxia-related Disease Research Center, College of Medicine, Inha University) ;
  • Lee, Jae-Seon (Hypoxia-related Disease Research Center, College of Medicine, Inha University)
  • Received : 2018.10.12
  • Published : 2019.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cellular senescence, a permanent state of cell cycle arrest, is believed to have originally evolved to limit the proliferation of old or damaged cells. However, it has been recently shown that cellular senescence is a physiological and pathological program contributing to embryogenesis, immune response, and wound repair, as well as aging and age-related diseases. Unlike replicative senescence associated with telomere attrition, premature senescence rapidly occurs in response to various intrinsic and extrinsic insults. Thus, cellular senescence has also been considered suppressive mechanism of tumorigenesis. Current studies have revealed that therapy-induced senescence (TIS), a type of senescence caused by traditional cancer therapy, could play a critical role in cancer treatment. In this review, we outline the key features and the molecular pathways of cellular senescence. Better understanding of cellular senescence will provide insights into the development of powerful strategies to control cellular senescence for therapeutic benefit. Lastly, we discuss existing strategies for the induction of cancer cell senescence to improve efficacy of anticancer therapy.

Keywords

References

  1. Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37, 614-636 https://doi.org/10.1016/0014-4827(65)90211-9
  2. Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol 75, 685-705 https://doi.org/10.1146/annurev-physiol-030212-183653
  3. Deng Y and Chang S (2007) Role of telomeres and telomerase in genomic instability, senescence and cancer. Lab Invest 87, 1071-1076 https://doi.org/10.1038/labinvest.3700673
  4. Munoz-Espin D, Canamero M, Maraver A et al (2013) Programmed cell senescence during mammalian embryonic development. Cell 155, 1104-1118 https://doi.org/10.1016/j.cell.2013.10.019
  5. Storer M, Mas A, Robert-Moreno A et al (2013) Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155, 1119-1130 https://doi.org/10.1016/j.cell.2013.10.041
  6. Campisi J (2014) Cell biology: The beginning of the end. Nature 505, 35-36 https://doi.org/10.1038/nature12844
  7. Acosta JC and Gil J (2012) Senescence: a new weapon for cancer therapy. Trends Cell Biol 22, 211-219 https://doi.org/10.1016/j.tcb.2011.11.006
  8. Itahana K, Campisi J and Dimri GP (2004) Mechanisms of cellular senescence in human and mouse cells. Biogerontology 5, 1-10 https://doi.org/10.1023/B:BGEN.0000017682.96395.10
  9. Chang BD, Broude EV, Dokmanovic M et al (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59, 3761-3767
  10. Chang BD, Xuan Y, Broude EV et al (1999) Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808-4818 https://doi.org/10.1038/sj.onc.1203078
  11. Lee M and Lee JS (2014) Exploiting tumor cell senescence in anticancer therapy. BMB Rep 47, 51-59 https://doi.org/10.5483/BMBRep.2014.47.2.005
  12. Hernandez-Segura A, Nehme J and Demaria M (2018) Hallmarks of Cellular Senescence. Trends Cell Biol 28, 436-453 https://doi.org/10.1016/j.tcb.2018.02.001
  13. Myrianthopoulos V, Evangelou K, Vasileiou PVS et al (2019) Senescence and senotherapeutics: a new field in cancer therapy. Pharmacol Ther 193, 31-49 https://doi.org/10.1016/j.pharmthera.2018.08.006
  14. Herranz N and Gil J (2018) Mechanisms and functions of cellular senescence. J Clin Invest 128, 1238-1246 https://doi.org/10.1172/JCI95148
  15. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L et al (2003) A DNA damage checkpoint response in telomereinitiated senescence. Nature 426, 194-198 https://doi.org/10.1038/nature02118
  16. Suram A, Kaplunov J, Patel PL et al (2012) Oncogeneinduced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 31, 2839-2851 https://doi.org/10.1038/emboj.2012.132
  17. Shiloh Y (2006) The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31, 402-410 https://doi.org/10.1016/j.tibs.2006.05.004
  18. Celeste A, Petersen S, Romanienko PJ et al (2002) Genomic instability in mice lacking histone H2AX. Science 296, 922-927 https://doi.org/10.1126/science.1069398
  19. d'Adda di Fagagna F (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8, 512-522 https://doi.org/10.1038/nrc2440
  20. Lukas C, Falck J, Bartkova J, Bartek J and Lukas J (2003) Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 5, 255-260 https://doi.org/10.1038/ncb945
  21. Turenne GA, Paul P, Laflair L and Price BD (2001) Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. Oncogene 20, 5100-5110 https://doi.org/10.1038/sj.onc.1204665
  22. Acosta JC, Banito A, Wuestefeld T et al (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15, 978-990 https://doi.org/10.1038/ncb2784
  23. Yoshimoto S, Loo TM, Atarashi K et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101 https://doi.org/10.1038/nature12347
  24. Ohanna M, Giuliano S, Bonet C et al (2011) Senescent cells develop a PARP-1 and nuclear factor-${\kappa}B$-associated secretome (PNAS). Genes Dev 25, 1245-1261 https://doi.org/10.1101/gad.625811
  25. Wiley CD, Velarde MC, Lecot P et al (2016) Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab 23, 303-314 https://doi.org/10.1016/j.cmet.2015.11.011
  26. Kang C, Xu Q, Martin TD et al (2015) The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science 349, aaa5612 https://doi.org/10.1126/science.aaa5612
  27. Kuilman T and Peeper DS (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031 https://doi.org/10.1016/j.cell.2008.03.039
  28. Acosta JC, O'Loghlen A, Banito A et al (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018 https://doi.org/10.1016/j.cell.2008.03.038
  29. Laberge RM, Sun Y, Orjalo AV et al (2015) MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 17, 1049-1061 https://doi.org/10.1038/ncb3195
  30. Herranz N, Gallage S, Mellone M et al (2015) mTOR regulates MAPKAPK2 translation to control the senescenceassociated secretory phenotype. Nat Cell Biol 17, 1205-1217 https://doi.org/10.1038/ncb3225
  31. Hayakawa T, Iwai M, Aoki S et al (2015) SIRT1 suppresses the senescence-associated secretory phenotype through epigenetic gene regulation. PLoS One 10, e0116480 https://doi.org/10.1371/journal.pone.0116480
  32. Chen H, Ruiz PD, McKimpson WM et al (2015) MacroH2A1 and ATM play opposing roles in paracrine senescence and the senescence-associated secretory phenotype. Mol Cell 59, 719-731 https://doi.org/10.1016/j.molcel.2015.07.011
  33. Capell BC, Drake AM, Zhu J et al (2016) MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev 30, 321-336 https://doi.org/10.1101/gad.271882.115
  34. Jung SH, Lee M, Park HA et al (2018) Integrin ${\alpha}6{\beta}4$-Src-AKT signaling induces cellular senescence by counteracting apoptosis in irradiated tumor cells and tissues. Cell Death Differ 26, 245-259 https://doi.org/10.1038/s41418-018-0114-7
  35. Ohno-Iwashita Y, Shimada Y, Hayashi M and Inomata M (2010) Plasma membrane microdomains in aging and disease. Geriatr Gerontol Int 10, S41-52 https://doi.org/10.1111/j.1447-0594.2010.00600.x
  36. Kurz DJ, Decary S, Hong Y and Erusalimsky JD (2000) Senescence-associated ${\beta}$-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113, 3613-3622 https://doi.org/10.1242/jcs.113.20.3613
  37. Sadaie M, Salama R, Carroll T et al (2013) Redistribution of the Lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. Genes Dev 27, 1800-1808 https://doi.org/10.1101/gad.217281.113
  38. Salama R, Sadaie M, Hoare M and Narita M (2014) Cellular senescence and its effector programs. Genes Dev 28, 99-114 https://doi.org/10.1101/gad.235184.113
  39. Nardella C, Clohessy JG, Alimonti A and Pandolfi PP (2011) Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11, 503-511 https://doi.org/10.1038/nrc3057
  40. Kim WY and Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127, 265-275 https://doi.org/10.1016/j.cell.2006.10.003
  41. Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21, 525-530 https://doi.org/10.1101/gad.415507
  42. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Pro Natl Acad Sci U S A 93, 13742-13747 https://doi.org/10.1073/pnas.93.24.13742
  43. Wiley CD and Campisi J (2016) From ancient pathways to aging cells-connecting metabolism and cellular senescence. Cell Metab 23, 1013-1021 https://doi.org/10.1016/j.cmet.2016.05.010
  44. Jones RG, Plas DR, Kubek S et al (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18, 283-293 https://doi.org/10.1016/j.molcel.2005.03.027
  45. Wang W, Yang X, Lopez de Silanes I, Carling D and Gorospe M (2003) Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem 278, 27016-27023 https://doi.org/10.1074/jbc.M300318200
  46. Tran D, Bergholz J, Zhang H et al (2014) Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence. Aging Cell 13, 669-678 https://doi.org/10.1111/acel.12219
  47. Angelini F, Pagano F, Bordin A et al (2017) Getting old through the blood: Circulating molecules in aging and senescence of cardiovascular regenerative cells. Front Cardiovasc Med 4, 62 https://doi.org/10.3389/fcvm.2017.00062
  48. Michishita E, Park JY, Burneskis JM, Barrett JC and Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16, 4623-4635 https://doi.org/10.1091/mbc.e05-01-0033
  49. Ota H, Tokunaga E, Chang K et al (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176-185 https://doi.org/10.1038/sj.onc.1209049
  50. Huang J, Gan Q, Han L et al (2008) SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS One 3, e1710 https://doi.org/10.1371/journal.pone.0001710
  51. Langley E, Pearson M, Faretta M et al (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21, 2383-2396 https://doi.org/10.1093/emboj/21.10.2383
  52. Ong ALC and Ramasamy TS (2018) Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res Rev 43, 64-80 https://doi.org/10.1016/j.arr.2018.02.004
  53. Blume-Jensen P and Hunter T (2001) Oncogenic kinase signalling. Nature 411, 355-365 https://doi.org/10.1038/35077225
  54. Jung SH, Hwang HJ, Kang D et al (2018) mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene [Epub ahead of print]
  55. Schneider JL and Cuervo AM (2014) Autophagy and human disease: emerging themes. Curr Opin Genet Dev 26, 16-23 https://doi.org/10.1016/j.gde.2014.04.003
  56. Chang J, Lee S and Blackstone C (2014) Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation. J Clin Invest 124, 5249-5262 https://doi.org/10.1172/JCI77598
  57. Gewirtz DA (2013) Autophagy and senescence: A partnership in search of definition. Autophagy 9, 808 https://doi.org/10.4161/auto.23922
  58. Kang C and Elledge SJ (2016) How autophagy both activates and inhibits cellular senescence. Autophagy 12, 898-899 https://doi.org/10.1080/15548627.2015.1121361
  59. Young AR, Narita M, Ferreira M et al (2009) Autophagy mediates the mitotic senescence transition. Genes Dev 23, 798-803 https://doi.org/10.1101/gad.519709
  60. Mosieniak G, Adamowicz M, Alster O et al (2012) Curcumin induces permanent growth arrest of human colon cancer cells: link between senescence and autophagy. Mech Ageing Dev 133, 444-455 https://doi.org/10.1016/j.mad.2012.05.004
  61. Wang Y, Wang XD, Lapi E et al (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A 109, 13325-13330 https://doi.org/10.1073/pnas.1120193109
  62. Kim BC, Yoo HJ, Lee HC et al (2014) Evaluation of premature senescence and senescence biomarkers in carcinoma cells and xenograft mice exposed to single or fractionated irradiation. Oncol Rep 31, 2229-2235 https://doi.org/10.3892/or.2014.3069
  63. Ewald JA, Desotelle JA, Wilding G and Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102, 1536-1546 https://doi.org/10.1093/jnci/djq364
  64. Ovadya Y and Krizhanovsky V (2018) Strategies targeting cellular senescence. J Clin Invest 128, 1247-1254 https://doi.org/10.1172/JCI95149
  65. Yosef R, Pilpel N, Papismadov N et al (2017) p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling. EMBO J 36, 2280-2295 https://doi.org/10.15252/embj.201695553
  66. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 https://doi.org/10.1126/science.1092472
  67. Alimonti A, Nardella C, Chen Z et al (2010) A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 120, 681-693 https://doi.org/10.1172/JCI40535
  68. Gembarska A, Luciani F, Fedele C et al (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18, 1239-1247 https://doi.org/10.1038/nm.2863
  69. Harajly M, Zalzali H, Nawaz Z et al (2016) p53 restoration in induction and maintenance of senescence: Differential effects in premalignant and malignant tumor cells. Mol Cell Biol 36, 438-451 https://doi.org/10.1128/MCB.00747-15
  70. Baar MP, Brandt RMC, Putavet DA et al (2017) Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132-147 https://doi.org/10.1016/j.cell.2017.02.031
  71. Jung SH, Lee HC, Yu DM et al (2016) Heparan sulfation is essential for the prevention of cellular senescence. Cell Death Differ 23, 417-429 https://doi.org/10.1038/cdd.2015.107
  72. Lee JJ, Lee JH, Ko YG, Hong SI and Lee JS (2010) Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species. Oncogene 29, 561-575 https://doi.org/10.1038/onc.2009.355
  73. Stambolic V, Suzuki A, de la Pompa JL et al (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 https://doi.org/10.1016/S0092-8674(00)81780-8
  74. Trotman LC, Niki M, Dotan ZA et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1, E5 https://doi.org/10.1371/journal.pbio.0000005
  75. Chen Z, Trotman LC, Shaffer D et al (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 https://doi.org/10.1038/nature03918
  76. Lee JJ, Kim BC, Park MJ et al (2011) PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18, 666-677 https://doi.org/10.1038/cdd.2010.139
  77. Kalathur M, Toso A, Chen J et al (2015) A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun 6, 7227 https://doi.org/10.1038/ncomms8227
  78. Lapenna S and Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8, 547-566 https://doi.org/10.1038/nrd2907
  79. Campaner S, Doni M, Hydbring P et al (2010) Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12, 54-59 https://doi.org/10.1038/ncb2004
  80. Puyol M, Martin A, Dubus P et al (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 https://doi.org/10.1016/j.ccr.2010.05.025
  81. Lin HK, Chen Z, Wang G et al (2010) Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379 https://doi.org/10.1038/nature08815
  82. Kuilman T and Peeper DS (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9, 81-94 https://doi.org/10.1038/nrc2560
  83. Coppe JP, Desprez PY, Krtolica A and Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5, 99-118 https://doi.org/10.1146/annurev-pathol-121808-102144
  84. Coppe JP, Kauser K, Campisi J and Beausejour CM (2006) Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 281, 29568-29574 https://doi.org/10.1074/jbc.M603307200
  85. Coppe JP, Patil CK, Rodier F et al (2008) Senescenceassociated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853-2868
  86. Han NK, Kim BC, Lee HC et al (2012) Secretome analysis of ionizing radiation-induced senescent cancer cells reveals that secreted RKIP plays a critical role in neighboring cell migration. Proteomics 12, 2822-2832 https://doi.org/10.1002/pmic.201100419